Related Experiment Videos
Mitoxantrone-related acute leukemia in two MS patients
A Pielen1, S Goffette, V Van Pesch
1Service de Neurologie, Université catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Acta Neurologica Belgica
|January 1, 2009
Summary
Mitoxantrone treatment for multiple sclerosis (MS) is linked to a 0.65% leukemia risk. This risk, particularly for acute promyelocytic leukemia, appears dose-independent and occurs a median of 20 months post-treatment.
Area of Science:
- Oncology
- Neurology
- Hematology
Background:
- Mitoxantrone is an antineoplastic agent used in chemotherapy and for treating multiple sclerosis (MS).
- Leukemia is a significant concern in patients undergoing long-term cancer treatment.
Observation:
- Two new cases of mitoxantrone-related leukemia in MS patients are reported, occurring 14 and 18 months post-treatment.
- A literature review identified 29 additional cases, with an overall incidence rate of 0.65% in 2299 MS patients treated with mitoxantrone.
- Acute promyelocytic leukemia (APL) with the t(15;17) translocation was notably over-represented in MS patients compared to other cancer patients receiving mitoxantrone.
Findings:
- Leukemia occurrence following mitoxantrone treatment in MS patients is dose-independent.
- The mean latency period for leukemia development was 20 months after the cessation of mitoxantrone therapy.
Implications:
- This study highlights a specific risk of leukemia, particularly APL, in MS patients treated with mitoxantrone.
- The findings suggest careful monitoring for hematological malignancies in MS patients post-mitoxantrone therapy.
- Further research may be warranted to understand the mechanisms underlying this association and to refine treatment guidelines.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...